<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>500 patients who were admitted to hospitals in <z:hpo ids='HP_0011009'>acute</z:hpo> phases of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarctions</z:e> were treated by intravenous administrations of spasmolytical drugs </plain></SENT>
<SENT sid="1" pm="."><plain>518 patients with similar conditions, besides spasmolytical drugs received <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (<z:chebi fb="5" ids="28304">heparin</z:chebi> and phenilin) </plain></SENT>
<SENT sid="2" pm="."><plain>In patients with expressed <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">neurological disorders</z:e> treated by <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> there was a highly significant improvement, including an increase of the percent of moderate improvement and a drop in the <z:mp ids='MP_0010769'>lethality</z:mp>, In those patients with mildly expressed <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">neurological disorders</z:e> who received <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> an improvement was also marked, but not so distinctly </plain></SENT>
<SENT sid="3" pm="."><plain>In cases with slight <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">neurological disorders</z:e> the different outcomes were not significant </plain></SENT>
<SENT sid="4" pm="."><plain>The highest effectivesness of <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> was marked in infarctions, due to <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>The effectiveness indices in patients due to stenosis with angiospasms were not significant </plain></SENT>
</text></document>